JWC has taken the lead in organizing the growing information on CAMPs. It began with an international consensus document, which introduced CAMP as the new term for an increasing number and variety of products. The document outlined best practice in the use of CAMPs. JWC produced a digital infographic and held a webinar that served as a guide on implementing these recommendations into practice. Now, JWC is holding a CAMP summit. I am excited to attend the meeting particularly as it relates to the recommended evidence level required to receive reimbursement for CAMPs.

Thomas Serena, CEO & Medical Director, Serena Group

Cellular, Acellular, Matrix-like Products (CAMPs) are a therapeutic class that have been clinically proven to help re-establish the healing cascade, thus, affording hard-to-heal wounds the ability to progress to closure. Yet, a significant number of wound care providers do not consistently observe this favorable result secondary to not being properly educated on best practices related to CAMPs. The combination of inconsistent wound care provider training and restrictive regulatory policies seems to have hindered the adoption of CAMPs. We need to address this, urgently! The JWC CAMPs Summit will provide a platform to help all levels of wound care providers to better understand and drive best practices related to CAMPs . Furthermore, given the current regulatory landscape targeting CAMPs, this Summit could not be timelier and I encourage all involved in wound care to attend.

Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP

Cellular, Acellular and Matrix-Like Products Wound Care Summit will undoubtedly be a stimulating and thought provoking discussion among key KOLs. Participation is key in having an engaging discussion in regards to the intelectual concepts presented. There may be "pearls" coming from the attendees that will help frame the clinical use of CAMPs.

Greg Bohn, MD ABPM/UHM MAPWCA FACHM FAAWC